House Panel Blocks Federal Workers' Medical Cannabis Coverage
Congressional subcommittee votes 11-7 to prevent workers' comp from covering medical marijuana for federal employees despite rescheduling momentum.
The House Appropriations Subcommittee on Labor, Health and Human Services voted 11-7 to advance fiscal year 2027 spending legislation that explicitly prohibits federal workers' compensation programs from covering medical marijuana treatments. The narrow vote highlights ongoing congressional resistance to cannabis policy reform even as the Trump administration pursues rescheduling initiatives.
The prohibition creates a disconnect between evolving federal cannabis policy and employee benefits coverage. While rescheduling would remove cannabis from Schedule I status under the Controlled Substances Act, this appropriations language ensures federal workers cannot access medical marijuana through their compensation programs regardless of medical necessity or state-level legalization.
The vote exposes the complex regulatory landscape facing cannabis companies as they navigate conflicting federal policies. Major multi-state operators like Curaleev (CURLF), Trulieve (TCNNF), and Green Thumb Industries (GTBIF) continue building patient bases in state-legal markets while federal inconsistencies create operational challenges and limit institutional investment flows.
Cannabis industry advocates view federal employee benefits as a bellwether for broader acceptance. The subcommittee's action signals that congressional appropriators remain cautious about cannabis integration into federal programs, potentially slowing mainstream adoption even if rescheduling proceeds. This conservative approach could limit patient access expansion and delay the normalization process that investors anticipate will drive sector growth.
The legislation now advances to the full House Appropriations Committee, where cannabis provisions face additional scrutiny. Industry observers monitor these appropriations battles closely as they often preview broader congressional sentiment on cannabis policy. Federal employee coverage represents a significant potential patient population that remains off-limits to state-licensed operators, constraining market expansion opportunities in the nation's capital region and federal employment centers nationwide.